Nuvation Bio Collaborates With Thermo Fisher Scientific For Lung Cancer Treatment

Published: 2026-05-13 17:53:22 ET NUVB

Published on 05/13/2026 at 05:53 pm EDT

By Christopher Kuo

Nuvation Bio has tapped Thermo Fisher Scientific for U.S.-based final drug product manufacturing for a treatment for lung cancer.

Nuvation Bio, a New York-based oncology company, said it completed a technology transfer and product introduction to Waltham, Mass.-based Thermo Fisher Scientific for Ibtrozi, a treatment for Ros1-positive non-small cell lung cancer. The transition was submitted as a supplement to the Ibtrozi new drug application held by Nuvation Bio.

In June 2025, the Food and Drug Administration approved Ibtrozi for the treatment of adult patients with locally advanced or metastatic Ros1 non-small cell lung cancer.

Write to Christopher Kuo at [email protected]

(END) Dow Jones Newswires

05-13-26 1752ET